Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Brugia malayi | thymidylate synthase | 0.1095 | 0.0688 | 0.0659 |
Trypanosoma brucei | dihydrofolate reductase-thymidylate synthase | 0.3103 | 0.6131 | 1 |
Loa Loa (eye worm) | CMGC/CLK protein kinase | 0.0908 | 0.0181 | 0.0181 |
Trichomonas vaginalis | CMGC family protein kinase | 0.0908 | 0.0181 | 0.5 |
Leishmania major | protein kinase, putative | 0.0908 | 0.0181 | 0.0246 |
Mycobacterium tuberculosis | Dihydrofolate reductase DfrA (DHFR) (tetrahydrofolate dehydrogenase) | 0.4531 | 1 | 1 |
Echinococcus multilocularis | dual specificity protein kinase clk2 | 0.0908 | 0.0181 | 0.015 |
Echinococcus granulosus | hypothetical protein | 0.0897 | 0.015 | 0.012 |
Echinococcus granulosus | dihydrofolate reductase | 0.4531 | 1 | 1 |
Echinococcus granulosus | dual specificity protein kinase clk2 | 0.0908 | 0.0181 | 0.015 |
Schistosoma mansoni | serine/threonine protein kinase | 0.0908 | 0.0181 | 0.015 |
Trypanosoma cruzi | kinetoplastid kinetochore protein 10, putative | 0.0908 | 0.0181 | 0.0246 |
Toxoplasma gondii | bifunctional dihydrofolate reductase-thymidylate synthase | 0.3103 | 0.6131 | 1 |
Entamoeba histolytica | protein kinase, putative | 0.0853 | 0.0031 | 0.5 |
Leishmania major | dihydrofolate reductase-thymidylate synthase | 0.3103 | 0.6131 | 1 |
Trypanosoma cruzi | kinetoplastid kinetochore protein 19, putative | 0.0908 | 0.0181 | 0.0246 |
Trypanosoma brucei | kinetoplastid kinetochore protein 19 | 0.0908 | 0.0181 | 0.0246 |
Schistosoma mansoni | serine/threonine protein kinase | 0.0908 | 0.0181 | 0.015 |
Echinococcus multilocularis | thymidylate synthase | 0.1095 | 0.0688 | 0.0659 |
Echinococcus multilocularis | dihydrofolate reductase | 0.4531 | 1 | 1 |
Loa Loa (eye worm) | CMGC/DYRK/DYRK1 protein kinase | 0.0853 | 0.0031 | 0.0031 |
Onchocerca volvulus | 0.1095 | 0.0688 | 0.5 | |
Leishmania major | protein kinase, putative | 0.0908 | 0.0181 | 0.0246 |
Entamoeba histolytica | protein kinase, putative | 0.0853 | 0.0031 | 0.5 |
Echinococcus multilocularis | 0.0897 | 0.015 | 0.012 | |
Plasmodium falciparum | bifunctional dihydrofolate reductase-thymidylate synthase | 0.3103 | 0.6131 | 1 |
Echinococcus granulosus | thymidylate synthase | 0.1095 | 0.0688 | 0.0659 |
Entamoeba histolytica | hypothetical protein | 0.0853 | 0.0031 | 0.5 |
Schistosoma mansoni | bifunctional dihydrofolate reductase-thymidylate synthase | 0.1095 | 0.0688 | 0.0659 |
Entamoeba histolytica | protein kinase domain containing protein | 0.0853 | 0.0031 | 0.5 |
Trypanosoma cruzi | dihydrofolate reductase-thymidylate synthase | 0.3103 | 0.6131 | 1 |
Loa Loa (eye worm) | hypothetical protein | 0.0897 | 0.015 | 0.015 |
Brugia malayi | Protein kinase domain containing protein | 0.0908 | 0.0181 | 0.015 |
Plasmodium vivax | bifunctional dihydrofolate reductase-thymidylate synthase, putative | 0.3103 | 0.6131 | 1 |
Mycobacterium ulcerans | dihydrofolate reductase DfrA | 0.4531 | 1 | 1 |
Trypanosoma brucei | kinetoplastid kinetochore protein 10 | 0.0908 | 0.0181 | 0.0246 |
Trypanosoma cruzi | kinetoplastid kinetochore protein 19, putative | 0.0908 | 0.0181 | 0.0246 |
Trypanosoma cruzi | kinetoplastid kinetochore protein 10, putative | 0.0908 | 0.0181 | 0.0246 |
Schistosoma mansoni | dihydrofolate reductase | 0.4531 | 1 | 1 |
Giardia lamblia | Kinase, CMGC CLK | 0.0908 | 0.0181 | 0.5 |
Brugia malayi | Dihydrofolate reductase | 0.4531 | 1 | 1 |
Loa Loa (eye worm) | thymidylate synthase | 0.1095 | 0.0688 | 0.0688 |
Mycobacterium leprae | DIHYDROFOLATE REDUCTASE DFRA (DHFR) (TETRAHYDROFOLATE DEHYDROGENASE) | 0.4531 | 1 | 1 |
Loa Loa (eye worm) | dihydrofolate reductase | 0.4531 | 1 | 1 |
Chlamydia trachomatis | dihydrofolate reductase | 0.4531 | 1 | 0.5 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
MIC (functional) | = 0.2 ug ml-1 | Minimum inhibitory concentration required to reduce herpes simplex virus-1 (HSV-1 (F)) virus-induced cytopathicity by 50% | ChEMBL. | 8388474 |
MIC (functional) | = 0.2 ug ml-1 | Minimum inhibitory concentration required to reduce herpes simplex virus-1 (HSV-1 (McIntyre)) virus-induced cytopathicity by 50% | ChEMBL. | 8388474 |
MIC (functional) | = 0.25 ug ml-1 | Minimum inhibitory concentration required to reduce varicella-zoster virus (VZV (Oka)) virus-induced cytopathicity by 50% | ChEMBL. | 8388474 |
MIC (functional) | = 0.4 ug ml-1 | Minimum inhibitory concentration required to reduce herpes simplex virus-1 (HSV-1 (KOS)) virus-induced cytopathicity by 50% | ChEMBL. | 8388474 |
MIC (functional) | = 0.4 ug ml-1 | Minimum inhibitory concentration required to reduce vesicular somatitis virus (VSV (YS)) virus-induced cytopathicity by 50% | ChEMBL. | 8388474 |
MIC (functional) | = 5 ug ml-1 | Minimum inhibitory concentration required to reduce TK-VZV (07-1) virus-induced cytopathicity by 50% | ChEMBL. | 8388474 |
MIC (functional) | > 10 ug ml-1 | Minimum inhibitory concentration required to reduce cytomegalo virus (CMV (AD-169)) virus-induced cytopathicity by 50% | ChEMBL. | 8388474 |
MIC (functional) | > 10 ug ml-1 | Minimum inhibitory concentration required to reduce cytomegalo virus (CMV (Davis)) virus-induced cytopathicity by 50% | ChEMBL. | 8388474 |
MIC (functional) | = 14 ug ml-1 | Minimum inhibitory concentration required to reduce virus-induced cell growth by 50% | ChEMBL. | 8388474 |
MIC (functional) | = 17 ug ml-1 | Minimum inhibitory concentration required to reduce TK-VZV (YS/R) virus-induced cytopathicity by 50% | ChEMBL. | 8388474 |
MIC (functional) | > 200 ug ml-1 | Minimum inhibitory concentration required to reduce herpes simplex virus-2 (HSV-2 (G)) virus-induced cytopathicity by 50% | ChEMBL. | 8388474 |
MIC (functional) | > 200 ug ml-1 | Minimum inhibitory concentration required to reduce herpes simplex virus-2 (HSV-2 (196)) virus-induced cytopathicity by 50% | ChEMBL. | 8388474 |
MIC (functional) | > 200 ug ml-1 | Minimum inhibitory concentration required to reduce herpes simplex virus-2 (HSV-2 (Lyons)) virus-induced cytopathicity by 50% | ChEMBL. | 8388474 |
MIC (functional) | > 200 ug ml-1 | Minimum inhibitory concentration required to reduce TK-HSV-1 (B2006) virus-induced cytopathicity by 50% | ChEMBL. | 8388474 |
MIC (functional) | > 200 ug ml-1 | Minimum inhibitory concentration required to reduce thymidine kinase deficient-HSV-1 (VMW 1837) virus-induced cytopathicity by 50% | ChEMBL. | 8388474 |
MIC (functional) | > 200 ug ml-1 | Minimum inhibitory concentration required to reduce VSV virus-induced cytopathicity by 50% | ChEMBL. | 8388474 |
MIC (functional) | > 200 ug ml-1 | Minimum inhibitory concentration required to reduce vaccinia virus (VV) virus-induced cytopathicity by 50% | ChEMBL. | 8388474 |
MIC (functional) | = 400 ug ml-1 | Minimum concentration required to cause a microscopically detectable alteration of cell morphology | ChEMBL. | 8388474 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.
1 literature reference was collected for this gene.